Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTX · Real-Time Price · USD
21.65
+6.65 (44.33%)
At close: Jul 24, 2026, 4:00 PM EDT
21.89
+0.24 (1.11%)
After-hours: Jul 24, 2026, 7:58 PM EDT
Scribe Therapeutics Revenue
Scribe Therapeutics had revenue of $2.23M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $36.28M. In the year 2025, Scribe Therapeutics had annual revenue of $51.17M with 86.68% growth.
Revenue (ttm)
$36.28M
Revenue Growth
+86.68%
P/S Ratio
10.51
Revenue / Employee
$407,663
Employees
89
Market Cap
381.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.17M | 23.76M | 86.68% |
| Dec 31, 2024 | 27.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCTX News
- 2 days ago - Scribe Therapeutics opens at $25, IPO priced at $15 per share - TheFly
- 2 days ago - Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share - TheFly
- 2 days ago - Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share - TheFly
- 2 days ago - Scribe Therapeutics 8.58M share IPO priced at $15.00 - TheFly
- 3 days ago - Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 24 days ago - Scribe Therapeutics IPO Registration Document (S-1) - SEC
- 24 days ago - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO - Renaissance Capital